DECK — Deckers Outdoor Corporation

The tape, not the fundamentals, is driving sentiment. As of 2026-09-13 the stock was down 5.29% in a week, 10.89% in a month and 28.6% in three months, closing at $81.27 versus a 52-week range of $78.91–$122.29 — essentially at the low. The narrative is a HOKA deceleration story: HOKA grew 14.5% in the March-2026 quarter versus the 30%+ rates investors were used to, while UGG grew 9.2% and total company net income actually fell YoY in the two most recent reported quarters (-10.5% in Mar-2026, -6.6% in Jun-2026). Note the divergence: sell-side analysts remain constructive (consensus 'Buy', price targets clustered $113–$123, latest updates from Stifel at $133 and UBS at $161 per the research brief), so this is a market that has repriced the multiple hard while the analyst community has not yet capitulated.

Clear deceleration, not collapse. Revenue YoY: +20.1% (Sep-24), +17.1% (Dec-24), +16.9% (Jun-25), +9.1% (Sep-25), +7.1% (Dec-25), +9.6% (Mar-26), +5.7% (Jun-26) — the Jun-2026 quarter is the slowest in the visible 12-quarter window. Gross margin has been remarkably stable, oscillating 56–60% on seasonality with TTM gross margin of 57.8%, so there is no pricing or promotional collapse. Operating margin is where the pressure shows: the two most recent quarters compressed roughly 2 points YoY — 15.2% vs 17.1% in Jun-26 and 14.0% vs 17.0% in Mar-26 — while the December quarters remain the profit engine at ~31% operating margin and EPS of $3.33 (+11% YoY). Reported net income declined YoY in both of the last two quarters (-10.5% and -6.6%), yet diluted EPS was roughly flat (-3.0% and +1.1%), meaning buybacks are already doing meaningful work on the per-share line. Free cash flow is highly seasonal and lumpy — the Dec-2025 quarter alone generated $1.02B of FCF while Sep-25 was -$13.9M — but TTM FCF of ~$1.07B actually exceeds TTM net income of ~$1.01B, so earnings are cash-backed. Bottom line: this is growth normalization in a non-cyclical brand franchise, with modest margin compression from deliberate marketing/expansion spend, not demand destruction.

Cheap, and cheap against its own history. As of 2026-09-13 the stock traded at 11.5x trailing EPS of $7.34 and ~10.8x the FY2027 consensus EPS of $7.52, versus a 5-year average P/E of 20.6x — a ~48% discount. P/S is 2.00x versus a 5-year average of 3.47x, EV/EBITDA is 7.3x, and PEG is 1.42. The balance sheet makes the multiple look cheaper still: $1.60B of cash against an $11.07B market cap (14.5% of the cap in cash), zero long-term debt as of 2026-06-30, a 2.75 current ratio, and a debt-to-equity of 0.205. Ex-cash, the core operating business is being valued at roughly 9x forward earnings for a company with 57.8% gross margins, 22.7% operating margins, 41% ROE and 32.9% ROIC. That is a valuation that assumes permanent growth impairment.

The market is pricing roughly zero-to-negative growth while consensus still models ~7% EPS growth to $7.52 and ~7.5% revenue growth to $5.88B in FY2027. That gap is the entire investment case and the entire risk. Two readings: (1) the sell-side estimates are stale and will be cut, in which case 10.8x is not as cheap as it looks; or (2) the multiple has overshot a deceleration that is normalizing rather than deteriorating — Q1 FY2027 already beat on EPS, and the $3.5B buyback authorization increase announced with the May-2026 Q4 results (total ~$5.0B, roughly 45% of the current market cap) tells you what management thinks the shares are worth. Watch the October 22, 2026 Q2 FY2027 print: if FY2027 EPS guidance holds near $7.52 while the market pays ~11x, the stock is mispriced; if guidance breaks, the de-rating is not finished.

Unambiguously a downtrend as of 2026-09-13. RSI(14) stood at 33.59 — approaching but not yet at oversold — with the price 6.53% below the 20-day SMA, 14.95% below the 50-day SMA and 20.72% below the 200-day SMA. All three moving averages are above price and the 20/50/200 stack is bearishly ordered, with the stock at $81.27 versus a 52-week low of $78.91. There is no reversal signal here: no positive RSI divergence, no reclaim of the 20-day, no volume capitulation spike evident in the data. Timing implication: the fundamental case can be right while the entry is early. A long here is a bet against momentum; a more disciplined approach is to wait for either a higher low above $78.91 or a close back above the 20-day (roughly $87), and to treat the 200-day (roughly $102) as the level that would confirm a trend change.

• Discretionary consumer spending remains uneven under cost-of-living pressure, which hits UGG (a $150–$250 premium boot/lifestyle purchase) more directly than HOKA and creates volatility in domestic wholesale reorders and DTC traffic.
• Footwear is heavily import-exposed; tariff and trade-policy changes flow straight into landed cost and are the most plausible cause of the ~2-point operating-margin compression seen in the last two quarters, alongside higher marketing spend.
• FX translation risk: international is the faster-growing part of the business, so a stronger dollar mechanically dampens reported growth even when local demand is healthy.
• Sector rotation — capital continues to favor AI/tech and away from consumer cyclicals, which compresses the multiple the market is willing to pay for a mid-single-digit grower regardless of execution.
• Competitive intensity in performance running (On, Brooks, Nike, Adidas) is rising at exactly the moment HOKA's growth has slowed from 30%+ to ~14%; the category tailwind for running and comfort footwear is still real but share gains are no longer automatic.
• Freight and inventory-carrying costs matter more than usual given the September-quarter cash-flow losses that accompany the fall/winter inventory build.

• Q2 FY2027 earnings on October 22, 2026 — the single most important datapoint: it gives the first real read on fall/winter UGG sell-through and the holiday wholesale order book, and will either validate or break the $7.52 FY2027 EPS consensus.
• Execution of the enlarged ~$5.0B share repurchase authorization (increased by $3.5B alongside the May-2026 Q4 results), which at ~11x earnings accretes EPS meaningfully and provides a persistent bid under the stock at these levels.
• Continued HOKA product pipeline and international expansion, plus adjacent-brand activity such as Teva's September 2026 Trailpeak trail-running launch — any reacceleration in HOKA growth would be the fastest route to a multiple re-rating.
• UGG brand heat via collaborations (e.g. the UGG x Willy Chavarria Paris collection) and the brand's continued transformation from a seasonal boot into a year-round lifestyle staple.
• Annual shareholder meeting on September 14, 2026 — low probability of a surprise, but any capital-allocation or guidance commentary is worth noting given the stock is near 52-week lows.
• Any sign of stabilization in discretionary consumer spending, which would lift the whole footwear peer group's multiple.

• HOKA's growth deceleration is the core risk: from 30%+ to 14.5% last quarter, with no evidence yet of a floor. If HOKA prints high-single-digit or worse growth, the entire 'quality growth at a discount' thesis weakens and estimates get cut.
• Net income already declined YoY in the last two quarters (-10.5% and -6.6%). EPS is only flat-to-slightly-up because of buybacks — if buybacks slow or margins compress further, the per-share line breaks too.
• Operating-margin compression (~2 points YoY in the last two quarters) could extend if marketing spend, tariffs, or freight costs stay elevated while growth slows — that is the classic 'growth deceleration meets fixed cost deleverage' squeeze.
• UGG's dependence on discretionary consumer spending means a weaker-than-expected fall/winter season would hit the highest-margin quarter (December, ~31% operating margin, $3.33 EPS) hardest.
• Value-trap risk: the stock is -28.6% over three months and -20.7% below its 200-day SMA with no technical bottom in place. Cheap can get cheaper, and sell-side targets in the $113–$123 range have been persistently wrong for a year.
• Concentration risk in two brands — HOKA and UGG drive essentially all of the economics, so a brand-heat reversal in either is a single-point-of-failure for the whole thesis.

This is a genuinely good business trading at a genuinely cheap price for a reason the market may be over-extrapolating. At 10.8x forward earnings, ~9x ex-cash, with $1.60B of cash, zero long-term debt, 57.8% gross margins, 22.7% operating margins, 32.9% ROIC and a ~$5.0B buyback authorization against an $11.07B market cap, the price embeds a permanent growth impairment that the actual numbers — +5.7% revenue growth, an EPS beat, stable gross margins, TTM FCF of $1.07B exceeding net income — do not support. The honest caveat is that growth is decelerating and margins are compressing, and the technicals (RSI 33.59, price below all major moving averages as of 2026-09-13) say the market has not finished repricing. On a 12–18 month horizon the risk/reward skews favorably; on a 1–3 month horizon it could easily get worse before it gets better.

I applied a 15x multiple — a deliberate ~25% discount to the broad market, and well below Deckers' own 5-year average P/E of 20.6x, justified by the shift from 20% growth to mid-single-digit growth while crediting the 57.8% gross margin, 22.7% operating margin, 32.9% ROIC, net-cash balance sheet and buyback capacity — to FY2027 consensus EPS of $7.52, giving $112.80. Cross-checks support the level: an 11x EV/EBITDA on ~$1.30B of EBITDA less $1.60B of net cash implies ~$101, and a two-stage DCF (FCF0 ~$1.05B, 7% growth years 1-5 tapering to 4%, 2.5% terminal, 10% discount rate) implies ~$137; my $112.80 sits between them and below the $113-$123 sell-side consensus, which I consider the appropriate posture given the risk that FY2027 estimates get trimmed.